[Skip to Content]
[Skip to Content Landing]
March 27, 2013

Macrolides and BronchiectasisClinical Benefit With a Resistance Price

Author Affiliations

Author Affiliations: CF and Airways Microbiology Research Group (Drs Elborn and Tunney); Centre for Infection and Immunity, School of Medicine, Dentistry and Biomedical Sciences (Dr Elborn); and School of Pharmacy (Dr Tunney), Queen's University Belfast, Belfast, United Kingdom.

JAMA. 2013;309(12):1295-1296. doi:10.1001/jama.2013.2780

Bronchiectasis is a common condition. Although the true prevalence is unknown, the prevalence in the United States has been estimated to range from 4 per 100 000 in young adults to nearly 300 per 100 000 in persons 75 years and older.1,2 Although bronchiectasis is a pathological description, it describes a group of conditions of somewhat diverse etiology that result in impairment of innate immunity and chronic infection, which in turn result in bronchial damage and dilation of the airways.3 In general, when referring to the condition, cystic fibrosis (CF) is excluded for practical rather than scientific reasons and the condition is frequently identified as non–cystic fibrosis bronchiectasis.

First Page Preview View Large
First page PDF preview
First page PDF preview